Blockchain Registration Transaction Record

Ex-NHL Star Joins Biotech Firm to Advance Non-Hallucinogenic LSD Treatment

Former NHL star Daniel Carcillo joins BetterLife Pharma to advance BETR-001, a non-hallucinogenic LSD derivative for traumatic brain injury treatment.

This development matters because traumatic brain injuries affect millions worldwide, from athletes and military veterans to accident survivors, often leaving them with lifelong cognitive and mental health challenges. Current treatment options are limited, and the regulatory hurdles for traditional psychedelic therapies have slowed progress. BetterLife's non-hallucinogenic approach could provide breakthrough treatment without the legal and practical barriers of controlled substances, potentially offering relief to those suffering from post-concussion syndrome, cluster headaches, and migraines. The involvement of someone with firsthand TBI experience like Carcillo brings crucial patient perspective to drug development, increasing the likelihood that resulting treatments will address real-world needs effectively.